What is the current stock price of Diagnocure, Inc. (DGCRF)?

As of the latest market data, Diagnocure, Inc. (DGCRF) is trading at $0.00. The stock has seen a loss of 0.00% today.

Does Diagnocure, Inc. (DGCRF) pay a dividend?

Based on current data, Diagnocure, Inc. does not have a confirmed active dividend policy.

What is the market cap of Diagnocure, Inc.?

The current market capitalization of Diagnocure, Inc. (DGCRF) is approximately unavailable.

DGCRF

Diagnocure, Inc.·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.00

Company Profile

Diagnocure, Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test. It also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company was formerly known as DiagnoCure Inc. 9342-8530 Québec Inc. was founded in 1994 and is headquartered in Quebec, Canada.

Sector

Healthcare

Industry

Medical - Specialties

Employees

IPO Date

2009-09-08

Beta

-15.95

Websitewww.diagnocure.com↗